Editorial: Women in Drug Metabolism and Transport: 2021

Overview

Journal Front Pharmacol

Date 2022 Aug 22

PMID 35991904

Authors

Claudia Bregonzio

Sara Eyal

Franciska Erdo

Mariela Fernanda Perez

Affiliations

Soon will be listed here.

References

Huynh C, Henrich A, Strasser D, Boof M, Al-Ibrahim M, Zu Schwabedissen H . A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker. Clin Pharmacol Ther. 2021; 109(6):1648-1659. DOI: 10.1002/cpt.2154. View

Grimstein M, Yang Y, Zhang X, Grillo J, Huang S, Zineh I . Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology. J Pharm Sci. 2018; 108(1):21-25. DOI: 10.1016/j.xphs.2018.10.033. View

Mulcahy A, Hlavka J, Case S . Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. Rand Health Q. 2018; 7(4):3. PMC: 6075809. View

Pouzol L, Sassi A, Baumlin N, Tunis M, Strasser D, Lehembre F . CXCR7 Antagonism Reduces Acute Lung Injury Pathogenesis. Front Pharmacol. 2021; 12:748740. PMC: 8602191. DOI: 10.3389/fphar.2021.748740. View

Zhang H, Li C, Liu J, Wu M, Li X, Zhu X . Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects. Expert Opin Investig Drugs. 2020; 30(2):185-192. DOI: 10.1080/13543784.2021.1863371. View

Zhang H, Wu M, Zhu X, Li C, Li X, Sun J . A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects. Front Pharmacol. 2020; 11:01329. PMC: 7580200. DOI: 10.3389/fphar.2020.01329. View

Pouzol L, Baumlin N, Sassi A, Tunis M, Marrie J, Vezzali E . ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases. FASEB J. 2021; 35(3):e21431. DOI: 10.1096/fj.202002465R. View

Huynh C, Brussee J, Pouzol L, Fonseca M, Zu Schwabedissen H, Dingemanse J . Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans. Biomed Pharmacother. 2021; 144:112363. DOI: 10.1016/j.biopha.2021.112363. View

Muehlan C, Heuberger J, Juif P, Croft M, van Gerven J, Dingemanse J . Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clin Pharmacol Ther. 2018; 104(5):1022-1029. DOI: 10.1002/cpt.1046. View

10.

Singh I, Jose V, Patel R, Arora S . Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial. Indian J Pharmacol. 2021; 53(1):6-12. PMC: 8216120. DOI: 10.4103/ijp.IJP_346_19. View